QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NYSE:BHVN

Biohaven - BHVN Stock Forecast, Price & News

$18.56
+0.48 (+2.65%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.55
$18.57
50-Day Range
$12.61
$19.20
52-Week Range
$5.54
$20.57
Volume
914,315 shs
Average Volume
1.02 million shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.32

Biohaven MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
214.2% Upside
$58.32 Price Target
Short Interest
Bearish
7.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Biohaven in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.82) to ($4.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

474th out of 1,029 stocks

Pharmaceutical Preparations Industry

225th out of 504 stocks

BHVN stock logo

About Biohaven (NYSE:BHVN) Stock

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial to treat spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in Sept 2022. The company was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Why Biohaven Stock Skyrocketed Again Today
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
11/09/2022
Today
2/07/2023
Next Earnings (Estimated)
2/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.32
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+214.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-846,590,000.00
Net Margins
-108.04%
Pretax Margin
-127.29%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
($11.34) per share

Miscellaneous

Free Float
59,709,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
1.08

Key Executives

  • Dr. Vladimir Coric M.D. (Age 51)
    Chairman & CEO
  • Mr. Matthew Buten (Age 61)
    Chief Financial Officer
  • Mr. George C. ClarkMr. George C. Clark (Age 38)
    VP & Chief Accounting Officer
  • Dr. Bruce D. Car DACVP (Age 61)
    Ph.D., Chief Scientific Officer
  • Ms. Jennifer Porcelli
    VP of Investor Relations
  • Mr. Warren Volles
    Gen. Counsel & Chief Legal Officer
  • Mr. Clifford Bechtold M.S.
    Chief Compliance Officer
  • Ms. Kimberly GentileMs. Kimberly Gentile (Age 56)
    Sr. VP of Clinical Operations
  • Mr. John TiltonMr. John Tilton (Age 54)
    Chief Commercial Officer of Rare Diseases
  • Mr. Chris Barrett
    Sr. VP of Commercial Strategy, Common Disease













BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price forecast for 2023?

10 brokerages have issued 1-year price targets for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $154.00. On average, they anticipate the company's share price to reach $58.32 in the next twelve months. This suggests a possible upside of 221.0% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2023?

Biohaven's stock was trading at $13.88 at the beginning of the year. Since then, BHVN stock has increased by 30.9% and is now trading at $18.17.
View the best growth stocks for 2023 here
.

Are investors shorting Biohaven?

Biohaven saw a increase in short interest in December. As of December 30th, there was short interest totaling 4,180,000 shares, an increase of 65.2% from the December 15th total of 2,530,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is presently 3.2 days. Approximately 7.2% of the shares of the stock are short sold.
View Biohaven's Short Interest
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) issued its earnings results on Wednesday, November, 9th. The company reported ($1.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.53) by $0.78.

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven's stock symbol?

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven's major shareholders?

Biohaven's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARS Investment Partners LLC (0.83%), Simplex Trading LLC (0.00%), Equitec Proprietary Markets LLC (0.00%), Nisa Investment Advisors LLC (0.13%), TD Asset Management Inc (0.09%) and New York State Common Retirement Fund (0.07%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Matthew Buten, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends
.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven's stock price today?

One share of BHVN stock can currently be purchased for approximately $18.17.

How much money does Biohaven make?

Biohaven (NYSE:BHVN) has a market capitalization of $1.24 billion and generates $462.51 million in revenue each year. The company earns $-846,590,000.00 in net income (profit) each year or ($13.94) on an earnings per share basis.

How many employees does Biohaven have?

The company employs 928 workers across the globe.

How can I contact Biohaven?

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via phone at 203-404-0410 or via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 2/7/2023 by MarketBeat.com Staff